Botanix Pharmaceuticals Limited (ASX:BOT)

Australia · Delayed Price · Currency is AUD

0.0300

0.00 (0.00%)

Apr 29, 2026, 4:10 PM AEST

-92.59% (1Y)

Market Cap	81.61M
Revenue (ttm)	21.92M
Net Income (ttm)	-88.70M
Shares Out	2.72B
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,282,473
Average Volume	33,069,031
Open	0.0290
Previous Close	0.0300
Day's Range	0.0280 - 0.0310
52-Week Range	0.0280 - 0.4750
Beta	1.01
RSI	28.06
Earnings Date	May 28, 2026

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the t... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1984

Employees 11

Stock Exchange Australian Securities Exchange

Ticker Symbol BOT

Full Company Profile

Financial Performance

In fiscal year 2025, Botanix Pharmaceuticals's revenue was 5.79 million, an increase of 179.74% compared to the previous year's 2.07 million. Losses were -86.40 million, 522.9% more than in 2024.

Financial Statements

News

Botanix Pharmaceuticals Earnings Call Transcript: H1 2026

Sofdra prescriptions and revenue surged in the first half of FY2026, driven by strong sales force execution and a scalable fulfillment platform. A major capital raise is underway to fund growth, reduce COGS, and support expansion, with profitability targeted as platform efficiencies scale.

2 months ago - Transcripts

Botanix Pharmaceuticals Earnings Call Transcript: Q2 2026

Revenue and prescriptions for Sofdra grew strongly, with net revenue up 28% quarter-over-quarter and gross-to-net yield improving to 24%. Sales force expansion and a unique fulfillment platform are driving growth, while cost-saving initiatives and high physician intent to prescribe support a positive outlook.

3 months ago - Transcripts

Botanix Pharmaceuticals Earnings Call Transcript: Q1 2026

Q1 saw robust growth in Sofdra prescriptions and net sales, driven by an expanded sales force and strong fulfillment platform. Cost management improved margins and liquidity, with all resources focused on Sofdra's success and further market penetration.

6 months ago - Transcripts

Botanix Pharmaceuticals Earnings Call Transcript: Q4 2025

Q4 FY2025 saw a successful Sofdra launch, with gross sales up to $20.4M and net revenue at $4.3M, driven by rapid prescription growth and high refill rates. The company is well-funded, expanding its sales force, and expects to reach profitability without further capital needs.

9 months ago - Transcripts

Botanix Pharmaceuticals Transcript: Investor Update

Sofdra’s commercial launch is set for early 2025, leveraging a robust AI-powered digital and telemedicine platform to target the large, underserved hyperhidrosis market. Early patient engagement, strong reimbursement outlook, and scalable infrastructure position the product for rapid uptake and future portfolio expansion.

1 year ago - Transcripts